Market Dynamics:
The circulating cell-free tumor DNA market is driven by the rising incidence of cancer globally. According to WHO, cancer is the second leading cause of death globally and is responsible for over 10 million deaths annually. Early detection and treatment monitoring are crucial for improving cancer outcomes. ctDNA provides a non-invasive method of cancer monitoring throughout the course of treatment and is expected to witness increasing adoption. Another key factor driving market growth is the increasing adoption of liquid biopsies over conventional tissue biopsies due to their non-invasive nature and real-time detection capabilities. Liquid biopsies help overcome limitations of tissue biopsies such as sampling errors and poor access to tumor sites. These advantages make ctDNA a promising diagnostic and monitoring approach in oncology.

Key Takeaways
The Global Circulating Cell-Free Tumor DNA Market Size is expected to witness high growth, exhibiting CAGR of 22.9% over the forecast period, due to increasing preference for minimally invasive procedures.

For More Insights, Read: https://newsinsights123.blogspot.com/2023/12/circulating-tumor-cell-dna-is-fastest.html